Beta blocker choice may improve heart outcomes on dialysis
Treatments studied
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This phase 3 study tests whether a specific beta blocker selection on hemodialysis can improve cardiovascular outcomes. It focuses on certain beta blockers commonly used through the VA pharmacy and compares them in a randomized way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are receiving hemodialysis (dialysis through a machine)
- You currently take one of these VA pharmacy beta blockers: metoprolol, atenolol, labetalol, carvedilol, or bisoprolol
- You (or someone legally allowed to make decisions for you) can give consent
- You do not have a history of bad allergic reactions to either study medication
- Your care team agrees to sign a new medication order if you are randomized
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether carvedilol and metoprolol succinate work similarly in people with heart failure with reduced pumping ability. If you already need a beta-blocker, your doctor may compare which one fits better for your situation.
This trial compares two beta-blocker medications, carvedilol and metoprolol succinate, to see which one works better for people with heart failure who have an implantable cardioverter defibrillator (ICD). If you are currently taking metoprolol succinate, you may be able to switch to carvedilol and help researchers find the best treatment.
This early-phase study tests whether RVX000222 is safe and effective in people with end-stage kidney disease who receive hemodialysis. If you join, you’ll be carefully monitored to see how your body responds and whether it changes kidney-related health measures.
This trial tests whether a genetic test can help doctors choose the best beta blocker for people with heart failure who have mildly reduced pumping function. It aims to improve treatment by matching the drug to your genetic profile.
This trial tests different blood pressure goals for people receiving dialysis at a center. It aims to find which target is safest and most effective for managing blood pressure during treatment.
This study tests whether two common heart medicines, bisoprolol and verapamil, improve symptoms in adults with non-obstructive hypertrophic cardiomyopathy. It may help you and your care team understand which medicine works better for symptom control and heart function.
Hear when a new End Stage Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.